Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.

Disclosure: The author does not hold a position in RXRX.

← Back to Free Index

RXRX

Analysis as of: 2026-05-07

Recursion Pharmaceuticals, Inc.

Clinical-stage biotech company using its Recursion OS, automated labs, and proprietary data to discover drug candidates and run biopharma collaborations.

ai automation biotech healthcare

On Yahoo Finance ...

Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Execution-Driven Repricing Potential in AI Biotech

The upside is a shift from lumpy collaboration revenue to a hybrid of product sales, milestones, and better platform economics. That rerating needs two things: a workable REC-4881 approval path and at least one more internal clinical proof point.

Analysis

Thesis

Recursion is a proof-gated AI biotech: if 2026-2027 turns REC-4881 plus at least one more internal program into credible human and regulatory proof, the market can rerate it from cash-backed option value to a hybrid drug-and-platform company with meaningfully higher revenue quality by 2031.

Last Economy Alignment

Cheaper cognition helps Recursion because its value is tied to proprietary experiments, data, and owned drug assets rather than seat-priced software. The cap is that clinical outcomes and regulators, not model output alone, still control value capture.

Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple

4.5x (from 5 most recent analyses)

Reasoning

The upside case is a quality change in revenue, not just a bigger version of today. By 2031 Recursion can look like a hybrid company with one early commercial owned asset, a broader set of milestone- or royalty-bearing programs, and better-structured partner contracts. That mix can support a materially higher enterprise value on a much larger revenue base, while still staying below premium commercial biotech valuations because proof remains incomplete.

Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary

The central risk is that Recursion proves it can generate more data faster, but not better medicines faster. If REC-4881's path stays unclear and REC-1245 or other internal programs fail to become repeatable proof points, the stock can remain stuck near cash-backed option value while dilution slowly rises. The upside is attractive because that proof is not yet fully priced in, but it is still proof-gated.

Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Trends

Key Changes

On May 6, 2026, Q1 results reiterated operating cash burn below 390 for 2026 and runway into early 2028.
On May 6, 2026, management said FDA engagement for REC-4881 had begun, making the second half of 2026 the main proof gate.
On May 6, 2026, REC-4539 entered Phase 1 and REC-1245 early dose-escalation data remained supportive.
The May 12, 2026 Bank of America conference is the only near-term scheduled repricing surface, but likely with limited new disclosure.

Thesis update

No material change. The latest update improved confidence in execution discipline and pipeline breadth, but the core thesis is still gated by one regulatory proof point and one more internal clinical validation event.

Forecast update

Slightly lower than the prior run because I now weight slower monetization of follow-on internal assets and future financing drag a bit more heavily.

Upgrade to Builder to also access: Future Considerations

Last Economy Structure

AI Industrial Score

0.41

They do not just sell AI screens; they own labs, data, and drug programs, so cheaper AI can make their engine more useful instead of replacing it. The risk is simple: if human trials and regulators do not validate that engine, the market will keep treating it like an interesting toolset rather than a durable value creator.

Upgrade to Reader to also access: Score Decomposition, Confidence Level

Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility

Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target

$6.71

Upgrade to Reader to also access: Bull Case, Base Case, Bear Case

Next Arc Research